Related Experiment Videos
Etoposide and split-dose cisplatin in bronchogenic carcinoma
R C Lauer1, W B Fisher, K Pennington
1Department of Medicine, Indiana University, Indianapolis 46223.
American Journal of Clinical Oncology
|December 1, 1988
Summary
This study found that an innovative schedule of cisplatin and VP-16 for bronchogenic carcinoma caused unexpected severe toxicity, including fatal granulocytopenia and septic shock. The Hoosier Oncology Group (HOG) study was closed early due to these adverse events.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Bronchogenic carcinoma treatment often involves chemotherapy.
- Cisplatin and VP-16 are commonly used chemotherapeutic agents.
- Investigating novel drug schedules is crucial for optimizing cancer therapy.
Purpose of the Study:
- To evaluate the safety and efficacy of an innovative schedule of cisplatin and VP-16 in patients with bronchogenic carcinoma.
- To identify any unexpected toxicities associated with this novel treatment regimen.
Main Methods:
- The Hoosier Oncology Group (HOG) treated 13 patients with bronchogenic carcinoma.
- An innovative, non-standard schedule of cisplatin and VP-16 was administered.
- Patient outcomes and adverse events were closely monitored.
Main Results:
- Unexpected severe toxicity was observed in the patient cohort.
- Five deaths occurred secondary to granulocytopenia and septic shock.
- Three episodes of renal failure were documented.
Conclusions:
- The investigated schedule of cisplatin and VP-16 demonstrated significantly higher toxicity compared to standard regimens.
- This novel schedule is not recommended for clinical use in bronchogenic carcinoma.
- Further research into safer chemotherapy schedules is warranted.